Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Change in Accured Expenses (2016 - 2025)

Lipocine (LPCN) has disclosed Change in Accured Expenses for 13 consecutive years, with $63888.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 8.64% year-over-year to $63888.0, compared with a TTM value of -$542618.0 through Sep 2025, down 457.05%, and an annual FY2024 reading of -$297246.0, down 311.19% over the prior year.
  • Change in Accured Expenses was $63888.0 for Q3 2025 at Lipocine, down from $66369.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $472012.0 in Q2 2024 and bottomed at -$554554.0 in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$47553.2, with a median of $55888.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses surged 645.79% in 2022, then plummeted 917.74% in 2024.
  • Year by year, Change in Accured Expenses stood at -$554554.0 in 2021, then surged by 135.5% to $196888.0 in 2022, then plummeted by 60.3% to $78173.0 in 2023, then crashed by 574.65% to -$371045.0 in 2024, then surged by 117.22% to $63888.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for LPCN at $63888.0 in Q3 2025, $66369.0 in Q2 2025, and -$301830.0 in Q1 2025.